Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Nicholas Fidelman, MD (ucsf)
Headshot of Nicholas Fidelman
Nicholas Fidelman

Description

Summary

This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver metastases). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as radiofrequency ablation, transarterial embolization, yttrium-90 microsphere radioembolization, and cryoablation may help activate the immune system in order to shrink tumors that are not being directly targeted. Peptide receptor radionuclide therapy is a form of targeted treatment that is performed by the use of a small molecule, which carries a radioactive component attached to a peptide. Once injected into the body, this small molecule binds to some specific sites on tumor cells called receptors and emit medium energy radiation that can destroy cells. Because this radionuclide is attached to the peptide, which binds receptors on tumor lesions, the radiation can preferably be targeted to the tumor cells in order to destroy them. Giving pembrolizumab in combination with liver-directed therapy or peptide receptor radionuclide therapy may work better than pembrolizumab alone.

Official Title

A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic And/or Progressive Metastases

Details

Keywords

Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm, Neoplasms, Neuroendocrine Tumors, Pembrolizumab, Lutetium Lu 177 dotatate, Arterial Embolization, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization

Eligibility

Location

  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Nicholas Fidelman, MD (ucsf)
    Nicholas Fidelman, MD, is a Professor of Clinical Radiology at the University of California, San Francisco and UCSF Mount Zion. Dr. Fidelman received his medical degree from UCSF in 2002, and completed his residency in Diagnostic Radiology from UCSF in 2007, followed by a fellowship in Interventional Radiology from UCSF in 2008.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Nicholas Fidelman, MD
ID
NCT03457948
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 32 people participating
Last Updated